BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » CHAMP Private Equity Acquires Cell Care, Australia’s Largest Cord Blood Bank
CHAMP Private Equity Cell Care

CHAMP Private Equity Acquires Cell Care, Australia’s Largest Cord Blood Bank

October 11, 2018 By Cade Hildreth (CEO) Leave a Comment

CHAMP Private Equity is acquiring Cell Care, the largest cord blood bank within Australia, according to news released October 10, 2018, by the Australian Financial Review (AFR).  According to AFR, “It is understood CHAMP will take a controlling stake in the business, while some of the vending shareholders will retain a minority shareholding.”

Discover class-defining bioproduction tools.

The transaction has important implications for the global stem cell banking marketplace, because the AFR estimates the deal to have a price tag of more than $100 million.

With this price tag, Cell Care will be well capitalized to continue its research into therapeutic applications of cord blood and tissue stem cells and may be positioned to expand into new markets beyond Australia and Canada.

bitbio

As stated by the AFR, “Cell Care is a top-10 player in cord blood globally, with its blood and stem cells used worldwide in more than 40,000 medical procedures and predominantly to treat childhood leukaemia.”

CellCare and Insception Lifebank

In October 2016, BioInformant previously reported that Cell Care acquired the largest cord blood bank in Canada, Insception Lifebank. The  merger of Cell Care and Insception Lifebank was a powerful alliance, because it created one of the ten largest cord blood banks worldwide with more than 100K cord blood and tissue units in storage.

Pluristyx

It also positioned the companies to continue collaborative clinical trial and R&D activity.

The deal between Cell Care and Insception Lifebank was historic, because it was one of the first cross-continental acquisitions to occur within the cord blood banking industry. Prior to that time, industry consolidation was happening within specific regions of the world.

Global Cord Blood Industry Consolidation

This acquisition of Cell Care by CHAMP Private Equity is part of a larger trend occurring within the cord blood banking industry, which is the trend of industry consolidation. In addition to larger cord blood banks acquiring smaller cord blood banks, holding companies have also been emerging within the global cord blood industry, most notably Cryoholdco within Latin America and Sanpower Group within Asia.

iPSC-derived cardiomyocte therapy

Additionally, private equity groups are increasing their interest in the sector.

In June 2018, GI Partners acquired the largest private cord blood bank in the United States, Cord Blood Registry (CBR), for $530 million.  GI Partners, a private equity investment firm, bought CBR to pair it with California Cryobank (CCB), world’s premier donor sperm and egg bank. In doing so, GI Partners created a single entity that will be the global leader in stem cell storage and reproductive tissue services.

CHAMP Private Equity Group

Founded in 1987, CHAMP Private Equity is headquartered in Sydney, NSW, Australia. The company also has an office in Singapore, allowing it to “focus on Australia’s closest trading partners in Southeast Asia” and positioning it to “accelerate portfolio company groups outside of Asia.”

With this approach being a central strategy for CHAMP Private Equity, it will be interesting to see how it plans to introduce Cell Care to new markets beyond Australia and Canada.

According to its company profile: “The CHAMP Group is one of Australia’s most experienced private equity managers having first raised institutional capital more than 30 years ago. Since that time CHAMP has made more than 90 investments and deployed more than $3.5 billion in equity capital.”

Interestingly, the CHAMP has not traditionally focused on healthcare assets and this is its first acquisition within the cord blood banking industry.

To learn more about the recent acquisition of Cell Care by CHAMP Private Equity, read the news article by the AFR: CHAMP Private Equity buys Australian cord blood company

What do you think about this acquisition of Cell Care by a private equity group? What implications does it has for the larger cord blood banking marketplace? Share your thoughts in the comments.

5/5 - (2 votes)

Filed Under: Cord Blood, Stem Cell News Tagged With: acquisition, cord blood

Related

About Cade Hildreth (CEO)

Cade Hildreth is the Founder of BioInformant.com, the world's largest publisher of stem cell industry news. Cade is a media expert on stem cells, recently interviewed by the Wall Street Journal, Los Angeles Business Journal, Xconomy, and Vogue Magazine. 

Tell Us What You Think! Cancel reply

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Featured Posts

Cord Blood Market Segmentation

Cord Blood Market Segmentation – Biobanking, HSCT, Cellular Therapy, Genetic Manipulation, & Research Tools

CAR-T Companies

CAR-T Cell Companies Proliferate: List of CAR-T Companies Worldwide

Who discovered stem cells?

Who Discovered Stem Cells? The Answers Revealed

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.